Showcases Stock ranks Forex

Intercept Pharmaceuticals (ICPT)
16.85  0.43 (2.62%) 08-08 16:00
Open: 16.28 Pre. Close: 16.42
High: 16.87 Low: 16.01
Volume: 708,031 Market Cap: 502M
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in New York, New York.
Prices Prediction (Update @5:00pm)
If tomorrow: Open lower Open higher
High: 16.88 - 16.93 16.93 - 16.986
Low: 15.862 - 15.922 15.922 - 15.988
Close: 16.741 - 16.834 16.834 - 16.939
Stock Technical Analysis
Target: Six months: 19.70
One year: 23.01
Support: Support1: 13.86
Support2: 12.00
Resistance: Resistance1: 16.87
Resistance2: 19.70
Pivot: 14.25
Moving Averages: MA(5): 15.00
MA(20): 14.34
MA(100): 15.66
MA(250): 15.82
MACD: MACD(12,26): 0.24
Signal(12,26,9): -0.09
%K %D: %K(14,3): 95.73
%D(3): 76.58
RSI: RSI(14): 65.75
52-Week: High: 20.5
Low: 10.81
Change(%): 20.7
Average Vol(K): 3-Month: 806
10-Days: 1070
Price, MAs and Bollinger Bands
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.

[ ICPT ] has closed Bollinger Bands are 28.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
Stock chart
Stock News
Wed, 03 Aug 2022
Intercept Pharmaceuticals, Inc. (ICPT) CEO Jerry Durso on Q2 2022 Results - Earnings Call Transcript - Seeking Alpha

Wed, 03 Aug 2022
Intercept Pharma Tops Q2 EPS by 21c; Offers FY22 Revenue Guidance By - India

Wed, 03 Aug 2022
Intercept Pharma GAAP EPS of -$0.68, revenue of $71.76M (NASDAQ:ICPT) - Seeking Alpha

Wed, 27 Jul 2022
Intercept to Announce Second Quarter 2022 Financial Results on August 3, 2022 - Yahoo Finance

Sat, 23 Jul 2022
Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Given Consensus Rating of "Hold" by Analysts - MarketBeat

Tue, 19 Jul 2022
Contrasting Intercept Pharmaceuticals (NASDAQ:ICPT) & Aerovate Therapeutics (NASDAQ:AVTE) - Defense World

Financial Analysis
Price to Book Value: Underperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Underperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Exchange:  NASDAQ Global Select
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 29.71
Shares Float (M) 24.68
% Held by Insiders 4.50
% Held by Institutions 96.99
Shares Short (K) 10340
Shares Short Prior Month (K) 9760
Stock Financials
EPS -2.200
Book Value (p.s.) -12.510
Profit Margin -17.54
Operating Margin -11.80
Return on Assets (ttm)
Return on Equity (ttm)
Qtrly Rev. Growth -25.7
Gross Profit (p.s.) 12.130
Sales Per Share 12.416
EBITDA (p.s.) -1.398
Qtrly Earnings Growth
Operating Cash Flow (M)
Levered Free Cash Flow (M)
Stock Valuation
PE Ratio -7.66
PEG Ratio -0.53
Price to Book value -1.35
Price to Sales 1.36
Price to Cash Flow
Stock Dividends
Dividend Yield
Dividend Growth

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android